Am J Transplant, Volume 18, Suppl 3 Archives - Page 27 of 211 - ATC Abstracts

2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
J. Assaker,¹ N. Murakami,¹ S. Eskandari,¹ M. Uehara,¹ C. Nathan,² H. Li,³ G. Lin,² J. Azzi.¹
¹Transplantation Renal Center, Harvard Medical School, Boston; ²Microbiology and Immunology, Weill Cornell Medicine, New York; ³Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…
2018 American Transplant Congress
Improvement of Metabolic Function after Intra-Portal Allogeneic Islet Transplantation by Induction Treatment of the Non-Hematopoetic Erytropoetin Analogue Cibinetide in a Mouse Model
M. Yao,¹ M. Watanabe,^1,2 S. Sun,¹ B. Ericzon,¹ T. Lundgren,¹ M. Kumagai-Braesch.¹
¹Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden; ²Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
IntroductionRecently, we have demonstrated that cibinetide, a non-hematopoetic erytropoetin analogue, protected pancreatic islets from cytokine-induced damage and apoptosis and ameliorated the early inflammatory response following…
2018 American Transplant Congress
The TRANSFORM Study: Infection Outcomes with Everolimus Plus Reduced Calcineurin Inhibitor and Mycophenolate Plus Standard Calcineurin Inhibitor Regimens in De Novo Kidney Transplant Recipients
F. Vincenti, J. Cruzado, S. Mulgaonkar, V. Garcia, D. Kuypers, M. Buchler, F. Citterio, U. Huynh-Do, W-.L. Luo, P. Bernhardt, C. Sommerer.
TRANSFORM Study Group, Novartis Pharma AG, Basel, Switzerland.
Purpose: Post-transplant (Tx) bacterial and viral infections are known to affect graft and patient survival. Accumulating evidence supports the protective effect of everolimus (EVR) against…
2018 American Transplant Congress
Renal Function, Blood Pressure, and Histologic Changes in Living Kidney Transplant Recipients from Hypertensive Donors
T. Dienemann, J. Schellenberg, K. Amann, K. Heller, A. Weidemann.
Nephrology and Hypertension University Hospital Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany.
Little is known if a kidney from a hypertensive donor performs equally compared to a kidney from a non-hypertensive donor. The present study examines the…
2018 American Transplant Congress
Steroid Sparing Maintenance Immunosuppression is Associated with Decreased Mortality after Simultaneous Liver Kidney Transplantation
S. Weeks, X. Luo, C. Song, L. Pote, A. Gurakar, F. Navqi, B. Philosophe, A. Cameron, N. Desai, S. Ottmann, D. Segev, J. Garonzik Wang.
Johns Hopkins, Baltimore, MD.
Purpose: Significant variation in maintenance immunosuppression (mIS) regimens has been described between transplant centers for simultaneous liver kidney (SLK) transplant recipients; we sought to describe…
2018 American Transplant Congress
The Protective Effect of Multivisceral Transplantation on Intestinal Allograft Rejection – Its Correlation with T-Cell Macrochimerism from a Long-Term Prospective Study
P. Liou,¹ M. Martinez,¹ J. Fu,² M. Velasco,¹ A. Griesemer,¹ S. Lobritto,¹ J. Vittorio,¹ S. Ravella,¹ B. Levin,³ J. Emond,¹ M. Sykes,² T. Kato.¹
¹Center for Liver Disease and Transplantation, Columbia University, New York, NY; ²Columbia Center for Translational Immunology, Columbia University, New York, NY; ³Department of Biostatistics, Columbia University, New York, NY.
Objective Graft rejection remains the crux of intestinal transplantation. Although liver-inclusive grafts appear to be protective, the mechanism remains unknown. We hypothesize that T-cell macrochimerism…
2018 American Transplant Congress
Senolytic Drug Treatment Attenuates mtDNA-Mediated Inflammatory Injury in Old Donors and Prolongs Cardiac Allograft Survival
K. Minami,¹ M. Seyda,¹ T. Heinbokel,¹ Y. Nian,¹ M. Quante,¹ G. Liu,¹ R. Abdi,² T. Tchkonia,³ J. Kirkland,³ A. Elkhal,¹ S. Tullius.¹
¹Transplant Surgery Division, Department of Surgery, Brigham and Women's Hospital, Boston, MA; ²Transplantation Research Center, Brigham and Women's Hospital, Boston; ³Robert and Arlene Kogod Center on Aging, Mayo Clinic College of Medicine, Rochester, MN.
Introduction: Solid organ transplantation has seen a increase in the utilization of older organs. Here, we investigate how aging-associated kinetics of damage associated molecular patterns…
2018 American Transplant Congress
Outcomes Analysis of Liver Transplantation Combined with Neoadjuvant Therapy in Patients with Unresectable Locally-Advanced Cholangiocarcinoma
M. Wong,¹ J. Kim,¹ C. Eriksen,¹ T. Pearson,¹ J. Robbins,² B. George,³ M. Zimmerman,¹ J. Hong.¹
¹Div. of Transplant Surgery, Medical College of Wisconsin and Froedtert Hospital (MCW & FH), Milwaukee, WI; ²Dept. of Radiation Oncology, MCW & FH, Milwaukee, WI; ³Div. of Hematology/Oncology, MCW & FH, Milwaukee, WI.
Objective: Liver transplantation (LT) combined with neoadjuvant chemoradiation (NCR) in well-selected patients with unresectable cholangiocarcinoma (CCA) achieves excellent long-term recurrence-free survival. Current criteria for NCR-LT…
2018 American Transplant Congress
Disparity in Access to Kidney Allograft Offers among HIV+ Transplant Candidates
J. Cohen,¹ J. Locke,² B. Shelton,² R. Reed,² P. MacLennan,² D. Sawinski.¹
¹Renal Division, University of Pennsylvania, Philadelphia, PA; ²Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL.
Background: Despite having a demonstrated survival benefit with kidney transplantation, patients with chronic viral infections, such as HCV or HIV, face many barriers to transplantation,…
2018 American Transplant Congress
Disparate Candidate Selection Practices and Substantial Use of Low KDPI Kidneys in Combined Heart-Kidney and Liver-Kidney Transplantation, 2012-2016
R. Steiner,¹ J. Halldorson.²
¹Transplant Nephrology, University of California at San Diego School of Medicine, San Diego, CA; ²Transplant Surgery, Sharp Memorial Hospital/Balboa Nephrology, San Diego, CA.
Transplant professionals have struggled to formulate defensible standards for combined heart-kidney and liver-kidney transplantation (HKTs and LKTs). In these recipients, recovery of native renal function…